Kothari Rushabh: Phase 3 Study on Triple Metronomic Therapy Now Published in The Cancer Letter
Kothari Rushabh, Director at Oncowin Cancer Centre, shared a post on X:
“Under the aegis of CRSF and guidance of Vijay Patil, Vanita Noronha, Dr. Kumar sir, our long-awaited study on Triple Metronomic therapy was published in The Cancer Letter.
Please read and comment.
Phase 3, multicenter, randomised, pragmatic, superiority study for 2nd line head and neck cancer patients (platinum refractory/ineligible)
TMC (Erlotinib Plus Methotrexate Plus Celecoxib) vs NCCN physician choice (Taxanes, Capecitabine, Afatinib, Cetuximab, Checkpoint inhibitors)
– 16 centers(academic and nonacademic) across India
– 114 patients
– Real world control arm especially for LMIC (<5% usage of IO in 1st and 2nd line, 44% taxane, 32% Afatinib)
– PS2 included
– Lab and radiology criteria as per institutional practice
– OS as primary endpointMedian OS:
– 181 vs 123 days(HR: 0.58)
– Lesser toxicities, especially grade 3 to 5
– Cost effective
– Oral regimen
Implications Resource constraint settings: As access to Cetuximab and IO is difficult for many patients, this regimen becomes SOC post-platinum progression Others: IO is likely to be used in 1st line with platinum doublet, making it a relevant option in 2nd line
Efforts to build on this backbone are ongoing. IO with TMC and Platinum+Taxane+TMC are showing promising results. Clinical trials for same are ongoing under CRSF.
After Oral at ASCO 23, this is my first effort to publish an original article in a high-impact factor Journal. It took long but was worth it and full of learning. I will thank my family, mentors, colleagues and friends.”
Ashish Singh, Professor of Medical Oncology at Christian Medical College Vellore, shared this post on X, adding:
“Amazing collective effort from the group.. congratulations. research which matters and changes practice on the ground.. enough evidence to indicate that OMCT backbone with immunotherapy must be studied in a frontline trial..”
Title: Phase 3 randomized study of physician choice vs metronomic chemotherapy in platinum refractory/ineligible head and neck cancer in palliative setting with survival outcomes
Journal: The Cancer Letters
Authors: Rushabh Kothari, Vijay Patil, Ravi krishna Madala, Ravikant Singh, Vikas T. Talreja, Anand Pathak, Sameer Shrirangwar, Tanmoy Kumar Mandal, Sudeep Das, Siddharth Turkar, Nikhil Pande, Arun Chandrasekharan, Gunjesh Singh, Tara Chand Gupta, Bhavesh Poladia, Manuprasad Avaronnan, Lovin Wilson, Nirmal Raut, Monica Jadhav, Mitali Alone, Manali Kolkur, Priyanka Bhagyavant, Shruti Pathak, Zoya Peelay, Gaurang Modi, Itesh Khatwani, Palak Bhatt, Gautam Kumar, Bhavya Jha, Unnati Singh, Kamlesh Madankar, Nibedita Sen, Vaibhav Sonwani, Sonal Muley, Sajith Babu Thavarool, Bharat Bhosale, Rakesh Katna, Deepan Rajamanickam, Saravana Rajamanickam, Praveen Kumar Shenoy Vp, Ashay Karpe, S.D. Banavali, Vanita Noronha, Kumar Prabhash
Radiotherapy for Head And Neck Cancer: Types, Success Rate, Side Effects And More
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023